|
New study demonstrates ACTEMRA®
(tocilizumab) inhibits progression of joint damage in Rheumatoid Arthritis patients
Roche announced results from a new two year phase III study showing that ACTEMRA
can
significantly inhibit progression of structural damage to joints in patients with
rheumatoid arthritis (RA), a critical measure of effectiveness of an RA treatment.
The study also demonstrated that ACTEMRA reduces disease signs and symptoms at one year.
The LITHE study is the fifth international Phase III ACTEMRA trial to successfully
meet its primary endpoints in patients with moderate to sever RA.
The one year data from the LITHE trial showed a greater proportion of
patients treated with ACTEMRA (4mg/kg or 8mg/kg) plus methotrexate versus
placebo plus methotrexate over 52 weeks achieved a significant reduction in
the progression of structural joint damage, which is critical to RA patients
because joint damage leads to disability.
The study included 1,196 patients from 137 trial sites in 15 countries.
RA Facts:
More than 1% of the American population has RA.
75% of people with RA are women.
May is National Arthritis Month
Upcoming Events
DDW—Digestive Disease
Week
May 17-22, San Diego
Convention Center,
San Diego, CA
ONS—Oncology Nursing
Society
May 15-18 Pennsylvania
Convention
Center, Philadelphia,
PA
ACG—American College
of Gastroenterology
October 5-8, Gaylord
Palms and Resort, Orlando, FL
AASLD—American Association
for the
Study of Liver Disease
Oct 31-Nov 4,
Moscone West Convention Center, San
Francisco, CA
ASCO—American Society
of Clinical Oncology
May 30-June 3,
McCormick Place,
Chicago, IL
| 
4 million Americans are estimated to have HCV. 25,000 new infections are occurring every year.
